使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, and welcome to Harrow third-quarter 2026 earnings conference call. My name is Michelle, and I will be your operator for today's call. (Operator Instructions) As a reminder, this conference is being recorded.
早安,歡迎參加 Harrow 2026 年第三季財報電話會議。我是 Michelle,將擔任今天會議的接線員。(接線員指示)提醒各位,本次會議將被錄音。
I would now like to turn the call over to Mike Biega, Vice President of Investor Relations and Communications for Harrow. Please go ahead.
現在我想把電話交給 Harrow 投資人關係與傳播副總裁 Mike Biega。請開始。
Michael Biega - Vice President, Investor Relations & Communications
Michael Biega - Vice President, Investor Relations & Communications
Thank you, operator. Good morning, and welcome to Harrow's third-quarter 2026 earnings conference call. My name is Mike Biega, Vice President of Investor Relations and Communications.
謝謝,接線員。早安,歡迎參加 Harrow 2026 年第三季財報電話會議。我是 Mike Biega,投資人關係與傳播副總裁。
The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies and FDA approval of certain drug candidates in a timely manner or at all.
公司發言可能包含符合聯邦證券法定義的前瞻性陳述。前瞻性陳述受到眾多風險與不確定性影響,其中許多超出 Harrow 的控制範圍,包括公司不時在向 SEC 提交的文件中所描述的風險與不確定性,例如與公司能否將其 FDA 核准產品、配製(compounded)製劑與技術商業化,以及某些藥物候選品能否及時獲得 FDA 核准(或根本無法獲准)相關的風險與不確定性。
For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. Harrow's results may differ materially from those projected. Harrow disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise.
關於上述風險與不確定性的清單與說明,請參閱公司最近一期 Form 10-K 年報以及其後向美國證券交易委員會提交的 Form 10-Q 季報中的「風險因素」章節。Harrow 的實際結果可能與預測存在重大差異。Harrow 不承擔、亦無意更新或修訂任何財務預測或前瞻性陳述之義務,無論係因新資訊、未來事件或其他原因。
This conference call contains time-sensitive information and is accurate only as of today. Additionally, Harrow will refer to non-GAAP financial metrics, specifically Adjusted EBITDA. A reconciliation of any non-GAAP measures with the most directly comparable GAAP measure is included in the company's earnings release and letter to stockholders, both of which are available on the website.
本次電話會議包含具時效性的資訊,且僅截至今日為準。此外,Harrow 將提及非 GAAP 財務衡量指標,特別是調整後 EBITDA。任何非 GAAP 指標與最直接可比 GAAP 指標之對帳表,已包含於公司新聞稿及致股東函中,兩者皆可於公司網站取得。
Joining me on today's call are Mark Baum, Founder, Chairman, and Chief Executive Officer; Andrew Boll, President and Chief Financial Officer; Patrick Sullivan, Chief Commercial Officer; and Amir Shojaei, Chief Scientific Officer. With that, I would like to turn the call over to Mark. Mark?
今天與我一同參與電話會議的還有:創辦人、董事長兼執行長 Mark Baum;總裁兼財務長 Andrew Boll;商務長 Patrick Sullivan;以及科學長 Amir Shojaei。接下來,我想把電話交給 Mark。Mark?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Thanks, Mike, and good morning, everyone. Last quarter, I was clear. Our priority was turning the demand we were building into revenue. In the third quarter, that's exactly what happened, and it's the clearest sign yet that the second half is playing out as we expected. Demand is growing across key products, our expanded commercial team is getting more productive every month, and we're reaffirming our full-year revenue guidance.
謝謝,Mike,各位早安。上個季度,我說得很清楚。我們的優先事項是把正在建立的需求轉化為營收。在第三季,這正是發生的事情,這也是迄今最清楚的跡象,顯示下半年正如我們預期般推進。關鍵產品的需求正在成長,我們擴編的商業團隊每個月都更具生產力,我們也重申全年營收指引。
We're continuing our momentum, and I expect the fourth quarter to be the strongest quarter in Harrow's history. I also believe you will see our momentum continue into 2027. You see it in VEVYE, which delivered record revenue as our expanded sales force matures and begins to deliver improved prescription economics. You see it in TRIESENCE, which had its strongest quarter under Harrow ownership.
我們持續延續動能,我預期第四季將是 Harrow 歷史上最強的一季。我也相信各位將看到我們的動能延續到 2027 年。這可從 VEVYE 看出來:隨著我們擴編的銷售團隊日趨成熟並開始帶來更佳的處方經濟效益,VEVYE 創下營收新高。這也可從 TRIESENCE 看出來:在 Harrow 持有期間,TRIESENCE 迎來最強的一季。
You see it in IHEEZO, which heads into its historically strongest quarter with new clinical evidence from QUELL. An important part of the story is how we are organizing our commercial business to maximize the opportunities ahead. With the addition of TYRVAYA, we realigned our commercial organization into four focused teams: ocular surface disease, retina, surgical, and access plus, each built around the same prescribers, care settings, and purchasing dynamics.
這也可從 IHEEZO 看出來:在來自 QUELL 的新臨床證據支持下,IHEEZO 正邁入其歷來最強的一季。故事的重要一環,是我們如何組織商業業務,以最大化未來機會。隨著 TYRVAYA 的加入,我們將商業組織重新調整為四個聚焦團隊:眼表疾病、視網膜、手術,以及 access plus;每個團隊皆圍繞相同的處方醫師、照護場域與採購動態來建構。
Our largest team now serves one of the largest opportunities we have, namely ocular surface disease, including dry eye, where we now own two completely differentiated products in the category. Our new commercial structure allows our representatives to promote a broader portfolio of complementary products to the same customers, making every relationship and every sales call more productive. We have always benefited from commercial leverage, but this organization takes that advantage to another level.
我們目前最大的團隊服務於我們最大的機會之一,也就是眼表疾病(包括乾眼症);在此類別中,我們現在擁有兩項完全差異化的產品。新的商業架構讓我們的業務代表能向同一批客戶推廣更廣泛、彼此互補的產品組合,使每段關係與每一次拜訪都更具生產力。我們一向受益於商業槓桿效應,但這個組織架構把這項優勢提升到另一個層次。
With the launch of HarrowRx, we are making it even easier for those customers to access our entire portfolio through a single destination integrated into their existing workflows, primarily their EMRs. The G-MELT program, which we launched over 10 years ago, has been a true labor of love and is the first program Harrow took from idea to now, in a matter of weeks, an NDA filing.
隨著 HarrowRx 的推出,我們讓客戶更容易透過單一入口取得我們的完整產品組合,並整合到他們既有的工作流程中,主要是他們的 EMR。G-MELT 計畫是我們在 10 多年前啟動的,確實是一項傾注心力的成果,也是 Harrow 第一個從構想到如今、在短短數週內就完成 NDA 申請送件的計畫。
When our NDA is accepted for review and we receive our PDUFA date, which will hopefully be in 2027, it will be a tremendous accomplishment for the entire Harrow family and for our stockholders alike. I am thrilled that we will soon hopefully have the opportunity to reduce or eliminate the need for IVs and opioids in cataract surgery for millions of Americans each year, Amir is going to cover our NDA filing a bit more shortly.
當我們的 NDA 被受理進入審查,並收到我們的 PDUFA 日期(希望會在 2027 年),這將是整個 Harrow 大家庭以及我們股東的一項重大成就。我非常振奮,因為我們很快(希望如此)將有機會為每年數以百萬計接受白內障手術的美國人降低或消除對靜脈輸液與鴉片類止痛藥的需求;Amir 稍後會更進一步說明我們的 NDA 申請。
In summary, today, Harrow has more products, stronger commercial capabilities, and more ways to grow than at any point in our history, but we are not done building. We are not done building, but the emphasis has shifted from building the platform to excellence in commercial execution and delivering financial results. With that, I will turn it over to Andrew to walk through the financials and our outlook. Andrew?
總結來說,今天的 Harrow 擁有比歷史上任何時點更多的產品、更強的商業能力,以及更多的成長途徑,但我們尚未完成建設。我們尚未完成建設,但重點已從打造平台轉向卓越的商業執行與交付財務成果。接下來我把時間交給 Andrew,請他說明財務表現與我們的展望。Andrew?
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Good morning, everyone, and thank you for joining our call today. Third-quarter revenue was a record $99.3 million, up 41% sequentially and 39% year over year. Branded revenue was $83.5 million, up about 62% year over year, and made up roughly 84% of total revenue. VEVYE generated $39.7 million, IHEEZO $25.3 million, and TRIESENCE $10.7 million in revenue. Compounded revenue was $15.8 million. VEVYE was a clear example of demand converting to revenue.
各位早安,感謝今天加入我們的電話會議。第三季營收創下紀錄,達 9,930 萬美元,較前一季成長 41%,年增 39%。品牌產品營收為 8,350 萬美元,年增約 62%,約占總營收的 84%。VEVYE 貢獻 3,970 萬美元、IHEEZO 2,530 萬美元、TRIESENCE 1,070 萬美元營收。配製(compounded)營收為 1,580 萬美元。VEVYE 是需求轉化為營收的明確例證。
Revenues grew 35% sequentially, outpacing prescription growth as our changes to prescription economics took hold. GAAP gross margin was 75%, consistent with a year ago, and an improvement from Q2 gross margins of 71%. Still, our gross margins are lower than we expected, and this is largely a result of lower gross margins coming from our compounding revenue and product mix. SG&A was $53.1 million, reflecting our expanded commercial organization and roughly flat quarter over quarter.
營收較前一季成長 35%,增幅超過處方量成長,因為我們對處方經濟效益的調整開始發揮作用。GAAP 毛利率為 75%,與一年前一致,且較第二季 71% 的毛利率有所改善。儘管如此,我們的毛利率仍低於預期,主要原因是配製(compounding)營收的毛利率較低以及產品組合影響。SG&A 為 5,310 萬美元,反映我們擴編的商業組織,且與前一季大致持平。
R&D was $10.3 million, which is a little higher than we expected, but the result of programs accelerating and coming in ahead of schedule, primarily reflecting G-MELT NDA enabling work and clinical studies for IHEEZO and TRIESENCE. We also recorded a one-time $5 million gain that is reflected as other income in our statement of operations.
研發費用為 1,030 萬美元,略高於我們預期,但這是因為多項計畫加速推進並提前於時程完成,主要反映 G-MELT NDA 申報所需的支援工作,以及 IHEEZO 與 TRIESENCE 的臨床研究。我們也認列一次性 500 萬美元收益,於損益表中列為其他收入。
This is related to the resolution and settlement of our litigation with OSRX dating back several years. GAAP net income was $9.8 million, and adjusted EBITDA was $21.2 million, versus an adjusted EBITDA loss of $1.2 million in Q2. We ended September with $75.3 million in cash and cash equivalents. Turning to our outlook, we are reaffirming full-year revenue guidance of $350 million to $365 million. That implies Q4 revenue of roughly $136 million to $151 million, or approximately 37% to 52% sequential growth.
這與我們與 OSRX 之間可追溯至數年前的訴訟案之解決與和解有關。GAAP 淨利為 980 萬美元,調整後 EBITDA 為 2,120 萬美元,相較第二季調整後 EBITDA 虧損 120 萬美元。我們在 9 月底的現金及約當現金為 7,530 萬美元。接著談到展望,我們重申全年營收指引為 3.50 億至 3.65 億美元。這意味著第四季營收約為 1.36 億至 1.51 億美元,約相當於較前一季成長 37% 至 52%。
It's a substantial step-up, and here's why we believe it's achievable. Over the past two years, Q3 to Q4 revenue growth averaged approximately 30%. This year, we believe we're entering the fourth quarter with considerably more momentum across our portfolio. VEVYE is benefiting from expanded insurance coverage, an enlarged sales force, and improving prescription economics.
這是一個相當大的躍升,以下是我們認為可達成的原因。過去兩年,Q3 到 Q4 的營收成長平均約為 30%。今年,我們認為在進入第四季時,我們的產品組合整體動能明顯更強。VEVYE 受惠於保險給付範圍擴大、銷售團隊擴編,以及處方經濟性改善。
IHEEZO is entering its historically strongest quarter, while TRIESENCE continues to gain traction in ocular inflammation, supported by our expanded surgical team, and BYOOVIZ sales are growing. On top of that, we have a new revenue contributor with TYRVAYA, which began contributing revenue in the fourth quarter. Taken together, these drivers give us confidence in our ability to deliver a strong finish to the year.
IHEEZO 正進入其歷來最強的季度,而 TRIESENCE 在眼部發炎領域持續取得進展,在我們擴增的手術團隊支持下,BYOOVIZ 的銷售也在成長。此外,我們還有一個新的營收貢獻者 TYRVAYA,已於第四季開始貢獻營收。綜合而言,這些驅動因素讓我們對於在年底交出強勁成績充滿信心。
Turning to profitability, we're updating our full-year Adjusted EBITDA outlook to more than $40 million, including more than $33 million in the fourth quarter, compared with our previous guidance of $80 million to $100 million. Let me provide some context around that change. Our first-half revenue shortfall and lower gross margins than we anticipated put us behind our original EBITDA expectations.
談到獲利能力,我們將全年調整後 EBITDA 展望更新為超過 4,000 萬美元,其中第四季超過 3,300 萬美元,相較於我們先前提供的 8,000 萬至 1 億美元指引。我來補充一些關於這項變更的背景。上半年營收未達預期,以及毛利率低於我們原先預估,使我們落後於最初的 EBITDA 預期。
At the time, we still saw a path to achieve our guidance, but it required a very strong second half, including a favorable mix of higher-margin products. We made meaningful progress in Q3, delivering $21.2 million in Adjusted EBITDA and bringing our year-to-date total to $7.3 million. But to reach the low end of our previous guidance, we would still need approximately $73 million in Q4 alone, and our third-quarter performance was simply not where we needed it to be.
當時,我們仍看到達成指引的路徑,但需要非常強勁的下半年表現,包括較高毛利產品的有利組合。我們在第三季取得實質進展,交出 2,120 萬美元的調整後 EBITDA,並使年初至今累計達到 730 萬美元。但若要達到先前指引的低端,我們仍需要僅在第四季就約 7,300 萬美元,而第三季的表現確實未達到我們所需的水準。
As we've worked through our fourth-quarter forecast, several things have also changed. We're moving forward with our G-MELT NDA submission this year, which brings the FDA filing fee and preparation-related expenses into Q4. We've also accelerated spending across several clinical and development programs, including QUELL, the Phase 3 TRIESENCE study, and Yochu. And we're absorbing transition costs and purchase accounting impacts associated with the TYRVAYA acquisition.
在我們推進第四季預測的過程中,也有幾件事發生了變化。我們將在今年推進 G-MELT NDA 送件,這使得 FDA 申請費用與準備相關支出落在第四季。我們也加速了多項臨床與開發計畫的支出,包括 QUELL、TRIESENCE 的第三期研究,以及 Yochu。此外,我們也在吸收與 TYRVAYA 收購相關的轉換成本與購買會計影響。
Mark and I believe accelerating these initiatives is the right decision for the business, even though it affects near-term profitability. Rather than depend on unusually favorable fourth-quarter product mix to offset those additional costs, we've established a more conservative Adjusted EBITDA outlook that reflects our current expectations.
Mark 和我認為,加速這些計畫對公司而言是正確的決策,即使這會影響短期獲利。我們不再依賴第四季產品組合異常有利來抵消這些額外成本,而是建立了更保守的調整後 EBITDA 展望,以反映我們目前的預期。
Importantly, we're providing a floor rather than a range. Our expectation is for more than $33 million in fourth-quarter adjusted EBITDA, and there is room to outperform that level depending on how the quarter develops. We're confident in the underlying momentum of the business and believe these investments will position us well heading into 2027.
重要的是,我們提供的是底線而非區間。我們預期第四季調整後 EBITDA 將超過 3,300 萬美元,且視季度進展仍有機會優於該水準。我們對業務的基本動能充滿信心,並相信這些投資將使我們在邁向 2027 年時處於有利位置。
I'll now turn things over to Pat to discuss some key commercial achievements and metrics.
接下來我把時間交給 Pat,請他分享一些關鍵的商業成就與指標。
Patrick Sullivan - Chief Commercial Officer
Patrick Sullivan - Chief Commercial Officer
Thanks, Andrew, and good morning. Starting with VEVYE, total prescriptions grew 17% sequentially and 83% year over year. Two factors stand out. First, we more than doubled the field team behind VEVYE this year, and newer representatives are becoming more productive in their territories. The second is economics. We focused on getting more patients onto covered therapy, and it's working. Covered prescriptions are rising with encouraging progress among Medicare patients that continued into October.
謝謝你,Andrew,大家早安。先從 VEVYE 談起,總處方量較前一季成長 17%,較去年同期成長 83%。有兩個因素特別突出。第一,我們今年將支援 VEVYE 的外勤團隊規模增加了一倍以上,新進代表在各自區域的生產力正逐步提升。第二是經濟性。我們專注於讓更多病患使用有給付的治療,且成效正在顯現。有給付的處方量正在上升,Medicare 病患方面也取得令人鼓舞的進展,並延續到 10 月。
That's improving the economics of every VEVYE prescription, and we keep adding coverage. We recently expanded our coverage through a major national plan covering approximately 10 million lives, effective January. That's our third coverage win this year and strengthens our position heading into 2027. TYRVAYA's integration is also progressing well. Approximately 40 experienced sales representatives and their managers joined us from Viatris and are already calling on many familiar practices.
這正在改善每一張 VEVYE 處方的經濟性,而我們也持續新增給付覆蓋。我們近期透過一個主要的全國性保險計畫擴大了給付覆蓋,該計畫涵蓋約 1,000 萬名受保人,並將於 1 月生效。這是我們今年第三次取得給付覆蓋的勝利,並強化我們在邁向 2027 年時的地位。TYRVAYA 的整合也進展順利。約 40 位資深業務代表及其主管自 Viatris 加入我們,並已開始拜訪許多熟悉的診所。
We're beginning to see prescription demand grow under Harrow. Now shifting to IHEEZO. Unit demand was 62,210, up 21% year over year. It declined about 5% from a record Q2 demand, reflecting both historically slower third-quarter procedure activity and elevated practice purchases of the prior single-unit presentations late in Q2. That said, we expect sequential demand growth and believe Q4 can set a new quarterly record.
我們開始看到在 Harrow 旗下處方需求成長。接著談 IHEEZO。單位需求為 62,210,較去年同期成長 21%。相較於創紀錄的第二季需求,下降約 5%,反映第三季歷來較慢的手術量,以及第二季末診所對先前單支包裝的採購增加。不過,我們預期需求將逐季成長,並相信第四季可創下新的單季紀錄。
The underlying IHEEZO trends are strong. Our customer base continues to grow, and new retina account wins, along with deeper penetration of existing accounts, have more than offset the units we lost when pass-through status expired in the ASC setting. As Amir will discuss next, QUELL gives our retina team something we've never had before: prospective, randomized data on IHEEZO and intravitreal injections, including encouraging findings on patient comfort and tolerability for patients who return for injections month after month.
IHEEZO 的基本趨勢依然強勁。我們的客戶基礎持續擴大,新取得的視網膜客戶,以及既有客戶更深度的滲透,已足以抵消在 ASC 場域通過式(pass-through)資格到期後我們流失的單位數。如 Amir 接下來將說明,QUELL 為我們的視網膜團隊帶來了前所未有的資料:針對 IHEEZO 與玻璃體內注射的前瞻性、隨機分派數據,其中包含對於每月反覆回診接受注射的病患,在舒適度與耐受性方面的令人鼓舞發現。
Now focusing on BYOOVIZ. BYOOVIZ went wide before it went deep. More practices placed initial orders than we expected, but many started small while validating reimbursement and purchasing. Early reimbursement experience has been favorable. Several accounts have reordered, and demand strengthened through September and into Q4. Our focus is turning initial orders into larger, more consistent purchasing, learnings that will inform the OPUVIZ launch in 2027.
現在聚焦 BYOOVIZ。BYOOVIZ 先廣後深。下初始訂單的診所數量超出我們預期,但許多診所先以小量開始,以驗證給付與採購流程。早期的給付經驗相當正面。已有多個客戶再次下單,需求在 9 月期間並延續至第四季持續增強。我們的重點正轉向將初始訂單轉化為更大且更穩定的一致性採購,這些經驗也將為 2027 年 OPUVIZ 的上市提供參考。
Now let's discuss TRIESENCE. Unit demand reached 20,022, up 37% sequentially and 110% year over year, our strongest quarter since we relaunched the product. Ocular inflammation is a key driver, and we're especially encouraged that practices are beginning to build TRIESENCE into their treatment protocols, which tends to make use and unit volumes more consistent and predictable over time.
接著談 TRIESENCE。單位需求達到 20,022,較前一季成長 37%,較去年同期成長 110%,為我們重新上市以來最強的一季。眼部發炎是關鍵驅動因素,我們尤其受到鼓舞的是,診所開始將 TRIESENCE 納入其治療流程,這通常會使使用情況與單位量隨時間變得更一致且更可預測。
Our fourth-quarter priorities are clear: build on VEVYE momentum and improving economics, accelerate IHEEZO's growth in its strongest season, deepen BYOOVIZ adoption, deliver TYRVAYA's first quarter under Harrow, and continue to grow TRIESENCE and the rest of our portfolio. We're entering the quarter with more ways to win than ever, and our team is ready.
我們第四季的優先事項很明確:延續 VEVYE 的動能並改善經濟性、在 IHEEZO 最強的旺季加速成長、深化 BYOOVIZ 的採用、交出 TYRVAYA 在 Harrow 旗下的第一個季度表現,並持續推動 TRIESENCE 及我們其餘產品組合的成長。我們帶著比以往更多的致勝途徑進入本季,我們的團隊已準備就緒。
With that, I'll turn it over to Amir.
接下來我把時間交給 Amir。
Amir Shojaei - Chief Scientific Officer
Amir Shojaei - Chief Scientific Officer
Thanks, Pat. I'll cover QUELL and G-MELT. Today, we're reporting top-line results from QUELL, our Phase 4 multi-site randomized double-masked study comparing IHEEZO with routine anesthesia in 231 patients undergoing intravitreal injections. Let me start with the primary endpoint. QUELL did not meet its primary endpoint of non-inferiority.
謝謝你,Pat。我將說明 QUELL 與 G-MELT。今天,我們公布 QUELL 的主要結果;QUELL 是我們的第四期、多中心、隨機分派、雙盲研究,比較 IHEEZO 與常規麻醉在 231 名接受玻璃體內注射病患中的表現。我先從主要終點開始。QUELL 未達成其非劣性主要終點。
The primary endpoint was successful ocular surface anesthesia, defined as a pain score of 0, meaning no pain, or one, meaning pressure only, both immediately before and immediately after the injection. That was achieved in 55.2% of IHEEZO patients compared with 59.7% receiving routine anesthesia, and the upper bound of the 95% confidence interval exceeded our pre-specified 12-point margin. The design context matters here. The study was designed assuming 88% of patients in each arm would achieve success.
主要終點為成功的眼表麻醉,定義為在注射前即刻與注射後即刻的疼痛評分為 0(代表無痛)或 1(代表僅有壓迫感)。IHEEZO 組達成比例為 55.2%,相較之下,接受常規麻醉者為 59.7%,且 95% 信賴區間的上限超過我們預先設定的 12 個百分點界值。此處研究設計背景很重要。本研究在設計時假設兩組各有 88% 的病患可達成成功。
The actual observed rate overall was only about 57%. At that rate, roughly 114 patients per arm could not produce a confidence interval narrow enough to fit within a 12-point margin. In other words, the primary endpoint was inconclusive. The study did not establish that IHEEZO was non-inferior, but it also did not establish that IHEEZO was inferior. For retina specialists and their patients, patient comfort, pain, and safety are critically important.
整體實際觀察到的比率僅約為 57%。以該比率計算,每組約 114 名患者將無法產生足夠狹窄、可落在 12 點界值內的信賴區間。換言之,主要終點並無定論。本研究未能證立 IHEEZO 具非劣效性,但也未能證立 IHEEZO 為劣效。對視網膜專科醫師及其患者而言,患者舒適度、疼痛與安全性至關重要。
That is where QUELL's exploratory secondary and safety findings are encouraging. Keep in mind that routine anesthesia in this study involved proparacaine drops followed by a potent subconjunctival lidocaine injection, essentially an injection before the injection. Despite that difference in how anesthesia was administered, cumulative pain scores immediately before and after the intravitreal injection were identical at 2.0 in both groups.
這正是 QUELL 的探索性次要終點與安全性發現令人鼓舞之處。請記住,本研究中的常規麻醉包含丙美卡因(proparacaine)滴眼液,接著施以強效的結膜下利多卡因注射,本質上是「在注射前先打一針」。儘管麻醉給藥方式存在差異,玻璃體內注射前後即刻的累積疼痛分數在兩組皆相同,均為 2.0。
Where we began to see differences was after the procedures. Patients receiving IHEEZO reported lower pain in the hours following the injection, with cumulative pain scores through 24 hours of 2.9 compared with 3.7 for routine anesthesia. We also observed encouraging findings related to ocular surface health. Patients receiving IHEEZO had less ocular surface staining following the procedure, with a mean increase of 1.7 compared with 3.2 for routine anesthesia.
我們開始看到差異是在處置之後。接受 IHEEZO 的患者在注射後數小時回報的疼痛較低,24 小時內的累積疼痛分數為 2.9,而常規麻醉為 3.7。我們也觀察到與眼表健康相關的令人鼓舞結果。接受 IHEEZO 的患者在處置後眼表染色較少,平均增加 1.7,相較之下常規麻醉為 3.2。
This suggests less damage to the ocular surface with IHEEZO. Importantly, staining in the untreated eye remained unchanged in both groups. Finally, looking at patient-reported dryness symptoms as measured by SPEED questionnaire, patients receiving IHEEZO experienced less worsening on the day of the injection, and by 24 hours, their symptoms had improved from baseline.
這顯示使用 IHEEZO 對眼表造成的損傷較少。重要的是,兩組中未治療眼的染色皆維持不變。最後,從以 SPEED 問卷衡量的患者自述乾澀症狀來看,接受 IHEEZO 的患者在注射當天惡化較少,且到 24 小時時,其症狀較基線有所改善。
To me, this illustrates why the primary endpoint doesn't tell the whole story. It measured whether patients met a pre-specified threshold at two time points, but didn't fully capture differences in pain and ocular comfort over the hours that followed. We also observed fewer adverse events with IHEEZO, 27% versus 47%, with no serious adverse events in either group. I would like to extend our sincere appreciation to all the investigators and all the patients who made this study possible.
對我而言,這說明為何主要終點無法呈現全貌。它衡量的是患者在兩個時間點是否達到預先設定的門檻,但未能充分捕捉其後數小時疼痛與眼部舒適度的差異。我們也觀察到 IHEEZO 的不良事件較少,為 27% 對 47%,且兩組皆無嚴重不良事件。我想向所有研究者以及所有使本研究得以完成的患者致上誠摯的感謝。
Overall, I'm encouraged by these data. Taken together, they provide valuable new clinical evidence about IHEEZO in intravitreal injection procedures, and we look forward to presenting the full results at the Hawaiian Eye & Retina Conference in January 2027. On G-MELT, we completed our pre-NDA meeting with the FDA and remain on track to submit the NDA later this month or the beginning of next month, which is meaningfully earlier than we originally expected.
整體而言,這些數據令我感到鼓舞。綜合來看,這些結果為 IHEEZO 用於玻璃體內注射處置提供了寶貴且新的臨床證據,我們也期待在 2027 年 1 月的 Hawaiian Eye & Retina Conference 發表完整結果。關於 G-MELT,我們已完成與 FDA 的 NDA 送件前會議,並仍按計畫於本月稍晚或下月初提交 NDA,這比我們原先預期明顯更早。
If approved, G-MELT could become the only on-label product for sedation during cataract surgery, giving patients effective sedation without an IV line or opioids in one of the most common surgical procedures in the US.
若獲核准,G-MELT 可能成為白內障手術鎮靜唯一的核准適應症(on-label)產品,讓患者在美國最常見的手術之一中,無需靜脈輸液管路或阿片類藥物即可獲得有效鎮靜。
With that, I'll turn the call back to the operator for questions.
接下來我把電話交回給接線員進行提問。
Operator
Operator
(Operator Instructions) Chase Knickerbocker, Craig-Hallum.
(接線員指示)Chase Knickerbocker,Craig-Hallum。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
Maybe just first on VEVYE, congrats on the continued progress there. Could you just discuss in further detail some of those business changes that you made in September in light of trying to improve net realized ASP from the product? Thanks.
先談 VEVYE,恭喜你們在那方面持續取得進展。能否更詳細說明一下,你們在 9 月為了提升該產品的淨實現 ASP(平均售價)而做出的部分商業變更?謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Hey, Chase. This is Mark. Thanks for the question. I appreciate the question, but we're in an intensely competitive market, and I'm going to elect to not answer the question, unfortunately. We don't want to reveal the specific algorithm that we use in order to improve VEVYE economics.
嗨,Chase。我是 Mark。謝謝你的提問。我很感謝這個問題,但我們所處市場競爭非常激烈,很遺憾我選擇不回答。我們不希望揭露我們用來改善 VEVYE 經濟性的具體演算法。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
Understood. Maybe just if you expect to see that impact notably in Q4 from those business rule changes.
了解。那或許請問你是否預期這些商業規則變更的影響會在第四季明顯反映出來?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Well, I can tell you without question that we are seeing improvement certainly in Medicare-covered prescriptions, and really, I think across the board. The number of offices that are willing to submit prior authorizations for their patients in order to access VEVYE is actually much higher than one would think. And critically, the number of prior authorizations that are getting approved, even when there isn't coverage, is significant.
嗯,我可以很肯定地告訴你,我們確實看到 Medicare 承保處方的改善,而且我認為幾乎是全面性的。願意為其患者提交事前授權(prior authorization)以取得 VEVYE 的診所數量,其實比一般人想像的要高得多。而且關鍵是,即使在沒有給付的情況下,獲核准的事前授權數量也相當可觀。
This is, I would say, over the last 60, 75 days, the first real concerted effort that our team has had in order to shift the ratio of covered to cash pay prescriptions. As we said on the call, the data is extremely encouraging. The VEVYE economics are certainly improving. They did in the third quarter, and I think you'll see that happen in the fourth quarter as well. Andrew, do you want to add to that?
我會說,在過去 60 到 75 天,這是我們團隊首次真正有組織地努力,去改變「承保處方」相對於「自費處方」的比例。如同我們在電話會議中所說,數據非常令人鼓舞。VEVYE 的經濟性確實正在改善。第三季已經改善,我認為第四季也會看到同樣情況。Andrew,你要補充嗎?
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Nothing to add, Mark.
沒有要補充的,Mark。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
And then just on, as far as where you think we are from a standpoint of that expanded commercial team, as far as productivity for VEVYE, obviously the volume growth remains impressive, and then kind of the foot on the gas that the new TYRVAYA reps kind of provide to the overall franchise. Secondly there, just last from me, Mark Baum, as you think about that coverage win in Q1, should we think about the impact there being similar to the impact we saw to Q1 from the CVS win, where we can kind of buck some seasonal trends of volumes in Q1? Thanks.
另外,就你認為我們在擴編後的商業團隊方面目前處於什麼狀態、以及 VEVYE 的生產力而言,顯然量的成長仍然令人印象深刻;同時,新加入的 TYRVAYA 業務代表也為整體產品線帶來更強的推進力。第二點,也是我最後一個問題,Mark Baum,當你看待第一季那個給付覆蓋的勝利時,我們是否應該把其影響視為類似於我們在第一季因 CVS 勝利所看到的影響,也就是我們能在第一季某種程度上抵消一些季節性量的趨勢?謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Sure. I'm going to take the second question because, as you know, I mean, part of the reason why we had a meaningful miss in the first half of this year, and I said this in the letter to stockholders, is because of the challenges that we had from a market access perspective with that big coverage win. I don't believe you're going to see those same issues with this new coverage win beginning next year. In fact, I don't want to guarantee it, but I can almost promise you that we won't see that same level of impact.
當然。我先回答第二個問題,因為如你所知,我們今年上半年之所以出現明顯落差,其中一部分原因——我也在致股東信中提到——是因為在那次大型給付覆蓋勝利之後,我們在市場准入方面遇到的挑戰。我不認為你會在明年開始的這次新覆蓋勝利上看到同樣的問題。事實上,我不想做出保證,但我幾乎可以承諾,我們不會看到同等程度的影響。
So this is a big win, and you're going to see, I think, a greater shift once again from cash pay prescriptions to covered prescriptions. Our economics overall on a covered prescription are meaningfully higher than they are on a cash pay prescription. So we're very excited about not only this recent coverage win, but the other coverage wins we've had with even smaller plans. So we're making real progress. We promised that we would make progress on covered prescriptions.
所以這是一個重大勝利,我認為你將再次看到自費處方轉向承保處方的更大幅度轉移。整體而言,承保處方的經濟性明顯高於自費處方。因此,我們不僅對這次最新的覆蓋勝利感到非常興奮,也對我們在其他較小方案上取得的覆蓋勝利感到振奮。我們正在取得實質進展。我們承諾過會在承保處方方面取得進展。
I think we're meeting that promise, and I think you'll see continued progress on coverage for VEVYE in 2027. That would be a new prediction. I think you'll see more coverage for VEVYE. There seems to be some good momentum there. In terms of the productivity of the sales force, Pat, you want to jump on that?
我認為我們正在兌現這個承諾,而且我認為你將在 2027 年看到 VEVYE 的給付覆蓋持續進展。這會是一個新的預測。我認為你會看到 VEVYE 獲得更多覆蓋;目前看起來有不錯的動能。至於銷售團隊的生產力,Pat,你要接著回答嗎?
Patrick Sullivan - Chief Commercial Officer
Patrick Sullivan - Chief Commercial Officer
Sure. Thanks, Mark, and thanks for the question. We're very excited and bullish on our new ocular surface disease team that's out there representing Harrow's portfolio. I mean, I think the products that they're representing really offers a whole suite of solutions to the ophthalmic community and really kind of lines with our vision of being the preferred partner moving forward.
好的。謝謝,Mark,也謝謝你的問題。我們對目前在外代表 Harrow 產品組合的新眼表疾病團隊感到非常興奮且看多。我的意思是,我認為他們所代表的產品確實為眼科社群提供了一整套解決方案,也與我們希望成為未來首選合作夥伴的願景相一致。
Our combined team now really is really early days in the process, but I would say is the way we've designed our footprints and our engagement plans, I think early days, but very, very positive on what we're seeing in the trends early, feedback from physicians, and ultimately the integration is going smoothly. So we're very encouraged with Q4 on what we're seeing early days and look forward to really good results as we build upon Q3.
我們的整合團隊目前確實仍處於流程非常早期的階段,但我會說,從我們如何設計我們的覆蓋版圖與客戶互動計畫來看,雖然還是早期,但我們在趨勢上看到的初步表現非常、非常正面,醫師端的回饋也是如此,而最終整合也進行得很順利。因此,對於第四季我們在早期所看到的情況感到非常振奮,也期待在第三季的基礎上持續推進,取得非常好的成果。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
Thank you.
謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
That's great. I think I'm excited because if you think about where we were at the beginning of the year in terms of the number of key account managers covering VEVYE versus today, it's more than tripled. When you think about the number of reps that were covering TYRVAYA before Harrow acquired it relative today, it's essentially doubled.
太好了。我想我之所以感到興奮,是因為如果你回想年初時,負責覆蓋 VEVYE 的關鍵客戶經理人數,對比今天,已經增加到三倍以上。再看 Harrow 收購 TYRVAYA 之前負責覆蓋 TYRVAYA 的業務代表人數,相較於現在,基本上也翻了一倍。
On top of all of that, two other really important products that we're seeing momentum with in terms of prescription volumes are VERKAZIA and NATACYN, and now housed within that ocular surface disease team are those two products. We now have all of those reps, and those are not hard push sales. When you have fungal infections and this is the only FDA-approved product for that condition, docs just simply need to know how to get access to NATACYN.
除此之外,另外兩個我們在處方量動能上看到明顯成長的重要產品是 VERKAZIA 與 NATACYN,而這兩個產品現在也都納入眼表疾病團隊之下。我們現在擁有所有這些業務代表,而且這些並不是需要強力推銷的產品。當你面對黴菌感染,而這又是該適應症唯一獲 FDA 核准的產品時,醫師其實只需要知道如何取得 NATACYN。
When patients have severe allergies, children have severe allergies, and doctors want to not prescribe steroids for those patients, this is really the only steroid-sparing product, VERKAZIA. Our reps are now letting them know about its availability. So we have a lot more people providing that access information, and I think you're going to see those big four products, the biggest being VEVYE, really leverage this increased sales force.
當病患有嚴重過敏、兒童有嚴重過敏,而醫師希望不要為這些病患開立類固醇時,VERKAZIA 其實是唯一真正的「減少類固醇使用(steroid-sparing)」產品。我們的業務代表現在正在讓他們知道這個產品的可取得性。因此,我們有更多人提供取得管道資訊,我認為你會看到這四大產品(其中最大的是 VEVYE)確實能充分運用這支擴編後的銷售團隊。
Operator
Operator
Lachlan Hanbury-Brown, William Blair.
Lachlan Hanbury-Brown,William Blair。
Lachlan Hanbury-Brown - Analyst
Lachlan Hanbury-Brown - Analyst
I guess first maybe just wanted to follow up on QUELL and sort of elaborate on the implications for IHEEZO in retina. Are you thinking about another study, or sort of where do you go from here? Do you need another study? Does this change plans to put it on the label? I guess if we could just start with your thoughts there.
我想先跟進一下 QUELL,並請你們進一步說明其對 IHEEZO 在視網膜領域的意涵。你們是否在考慮再做一項研究,或是接下來要怎麼走?你們需要再做一項研究嗎?這會改變把它寫進標籤(label)的計畫嗎?我想先從你們對此的看法開始。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Yeah. For us, and I'll ask Amir Shojaei to comment as well, for us, the key is medical messaging. The reason for investing in the study is not only for an amendment to the label, if possible, if that made sense, but I think critically, it's medical messaging. Being able to have a sales force go out and talk about the use of our product specifically in the intravitreal injection procedure. We have not had that to date. All of the studies that were done for IHEEZO were done in cataract surgery.
是的。對我們而言——我也會請 Amir Shojaei 一起補充——關鍵在於醫學訊息傳遞(medical messaging)。投資這項研究的原因,不只是為了在可行且合理的情況下,看看是否能對標籤做修訂(amendment),更重要的是醫學訊息傳遞。也就是讓銷售團隊能夠外出,針對我們產品在玻璃體內注射(intravitreal injection)程序中的使用進行溝通。到目前為止我們還沒有這樣的基礎。IHEEZO 先前所有的研究都是在白內障手術中完成的。
Now, we do have a robust data set for intravitreal injections. What we learned, I think, is that it's pretty hard to anesthetize the eye and have a zero or one pain outcome with not only IHEEZO, but with an injection of lidocaine. It's not easy. If you look at the data, I mean, we were within four patients of, or 4 percentage points of being equivalent to an injection, sort of mainlining the anesthesia into the eye. I was quite proud of the performance of the drug.
現在,我們確實已經累積了一套針對玻璃體內注射的扎實資料集。我想我們學到的是,要讓眼睛麻醉後達到「0 或 1 的疼痛結果」,不僅對 IHEEZO 而言很難,即便是注射利多卡因(lidocaine)也很難。這並不容易。如果你看數據,我們距離與注射(等於把麻醉直接打進眼內)達到等效,只差四位病患,或說只差 4 個百分點。我對這個藥物的表現感到相當自豪。
But the key for us are those secondary endpoints, being able to go out to an office and to say, look, your patients will have less pain after the injection from hours four to 24 hours, better ocular surface staining, and far fewer adverse events. We can now confidently, legally say that. Amir Shojaei, you want to add anything to that?
但對我們而言,關鍵在於那些次要終點(secondary endpoints):能夠到診所去說,你看,你的病人在注射後第 4 小時到 24 小時之間疼痛會更少、眼表染色(ocular surface staining)更好,而且不良事件更少。我們現在可以有把握、且在法律上合規地這麼說。Amir Shojaei,你要補充什麼嗎?
Amir Shojaei - Chief Scientific Officer
Amir Shojaei - Chief Scientific Officer
Again, the only thing I'll add is currently we don't have any plans for a second study or further studies in this line. That said, we do have quite a few ongoing studies with investigator-initiated trials within the IHEEZO franchise.
我唯一要補充的是,目前我們沒有規劃進行第二項研究或在這條線上再做更多研究。不過,我們在 IHEEZO 產品線(franchise)之下,確實有不少由研究者主導的試驗(investigator-initiated trials)正在進行中。
Lachlan Hanbury-Brown - Analyst
Lachlan Hanbury-Brown - Analyst
And maybe as a second question here, I noticed some comments in the Form 10-Q about how the licensing of TYRVAYA potentially breaches certain parts of the VEVYE licensing contract with Novaliq. Just wondering what the potential outcomes there could be. Like, could this ultimately require divesting TYRVAYA? I realize you probably can't say much, but can you give us any kind of clarity on what this could mean?
另外作為第二個問題,我注意到 10-Q 表格中有一些評論,提到 TYRVAYA 的授權可能違反與 Novaliq 的 VEVYE 授權合約中的某些條款。想請問可能的結果會是什麼?例如,最終是否可能需要剝離(divest)TYRVAYA?我知道你們可能不能說太多,但能否給我們一些釐清,這可能代表什麼?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Yeah. Well, first let me just say, Novaliq and Harrow has been a marriage made in heaven. We've been a phenomenal partner to them. They have been a phenomenal partner to us. If you look at the growth in VEVYE units and the progress that our team has made with that product, I think it's very difficult to conclude otherwise. It's just been a phenomenal relationship on both sides.
好的。首先我想說,Novaliq 和 Harrow 的合作可說是天作之合。我們一直是他們非常出色的合作夥伴。他們也一直是我們非常出色的合作夥伴。如果你看 VEVYE 的出貨單位成長,以及我們團隊在這個產品上取得的進展,我認為很難得出相反的結論。這一直是雙方都非常成功的合作關係。
As far as TYRVAYA goes, we are under confidentiality. We're in active discussions with them. I think we believe, and I also think they believe, that the addition of all of the salespeople, the investments that we've made as a result of the TYRVAYA acquisition really do benefit sales of VEVYE. So we're going to work through this process, and I would bet that after we're done, we'll probably have a stronger relationship with our partners at Novaliq than we do today.
至於 TYRVAYA,我們受到保密義務約束。我們正在與他們積極討論中。我想我們相信——我也認為他們也相信——因 TYRVAYA 收購而新增的所有銷售人員,以及我們所做的投資,確實有助於 VEVYE 的銷售。因此我們會把這個流程走完;我敢說,等我們處理完之後,我們與 Novaliq 夥伴的關係很可能會比現在更為緊密。
Lachlan Hanbury-Brown - Analyst
Lachlan Hanbury-Brown - Analyst
Thanks.
謝謝。
Operator
Operator
Steve Seedhouse, Cantor.
Steve Seedhouse,Cantor。
Steve Seedhouse - Analyst
Steve Seedhouse - Analyst
Wanted to dig in on BYOOVIZ a little bit. It sounds like you had a pretty defined internal model just in terms of what your expectations for that launch were going to be, and you mentioned more breadth, but maybe not as much depth early on from an order standpoint.
我想更深入問一下 BYOOVIZ。聽起來你們內部對這次上市的預期有一個相當明確的模型;你也提到覆蓋面更廣,但從訂單角度看,早期的「深度」可能沒有那麼高。
I was hoping you could just expand on that, maybe walk us through sort of going forward what that means, and then I am also curious to know what you have learned so far, how that sort of affects your expectations for the OPUVIZ launch next year.
希望你能再展開說明一下,帶我們理解接下來這代表什麼;另外我也好奇,你們目前學到的東西,會如何影響你們對明年 OPUVIZ 上市的預期。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Well, I will ask Pat to comment in a second, but what I would say is, when you launch a biosimilar into a fairly competitive category, to be clear, you really do not know what the uptake is going to be. We have very strong relationships in retina.
好,我等一下會請 Pat 補充。不過我想說的是,當你在一個競爭相當激烈的類別中推出生物相似藥(biosimilar)時,坦白說,你真的不知道採用速度(uptake)會是什麼樣子。我們在視網膜領域有非常強的關係基礎。
We have an incredible retina team, so the members of the Harrow family that are on the retina side of things are just extraordinary in their productivity, the relationships that they have, and the trust that they have built with their customers over many, many years, in most cases, certainly well before they even joined the Harrow family. But you are right. We were an inch deep and sort of a mile wide on the launch.
我們有一支非常出色的視網膜團隊,所以 Harrow 大家庭中負責視網膜業務的成員,在生產力、他們所建立的關係,以及多年來與客戶建立的信任方面都非常卓越;多數情況下,甚至在他們加入 Harrow 大家庭之前很久就已經建立起來了。不過你說得沒錯。我們這次上市在覆蓋上是「一吋深、但一哩寬」。
That can be troubling on the one hand, but the reality is we had a lot of doctors, many more doctors purchasing the product than we had actually initially modeled. So the question is can you get pull-through after their initial purchases? And they are not going to give you that revenue opportunity, those volumes, until they have gone through sort of the same buy-and-bill cycle that we have seen with IHEEZO and that we have seen with TRIESENCE and other products that we sell in the buy-and-bill category.
一方面這可能令人擔心,但現實是,實際購買產品的醫師數量遠高於我們最初模型的預估。所以問題在於:在他們首次採購之後,能否帶動後續拉動(pull-through)?而在他們走完我們在 IHEEZO、TRIESENCE 以及其他我們在「先買後請款(buy-and-bill)」類別所銷售產品中看到的同樣買入與請款循環之前,他們不會把那個營收機會與那些量體交給你。
And so, after they had gone through that cycle, we did see, and are seeing today, that follow-through purchasing, and I think that is the most important factor that I can convey on this conference call with respect to BYOOVIZ.
因此,在他們走完那個循環之後,我們確實看到——而且今天仍在看到——後續的持續採購;我認為這是我在這通電話會議中,針對 BYOOVIZ 能傳達的最重要因素。
We are getting those follow-through purchases, and I think in the fourth quarter, we are probably well ahead of our model, whereas in the third quarter, we were somewhat behind. But the opportunity to sell more units to more customers can certainly allow you to make up ground quickly.
我們正在獲得這些後續採購;我認為在第四季,我們可能大幅領先於我們的模型預期,而在第三季,我們則有些落後。但把更多單位賣給更多客戶的機會,確實能讓你很快把差距補回來。
Pat, do you want to add to that?
Pat,你要補充一下嗎?
Patrick Sullivan - Chief Commercial Officer
Patrick Sullivan - Chief Commercial Officer
Sure. Thanks, Mark, and thanks for the question. As Mark mentioned, I think the early stages of the launch in Q3, I think we garnered an awful lot of learnings. I think one of the unique things that Harrow has the ability to show up, unlike other organizations in the retina space with the biosimilars, we have the ability to leverage our other products like IHEEZO and TRIESENCE.
當然。謝謝你,Mark,也謝謝這個問題。如 Mark 提到的,我認為在第三季上市初期,我們獲得了非常多的學習。我認為 Harrow 有一個獨特之處:不同於視網膜領域其他做生物相似藥的組織,我們能夠運用我們的其他產品,例如 IHEEZO 和 TRIESENCE。
So this gives us a unique engagement approach. Specifically with BYOOVIZ, I think as Mark mentioned, one of the things that we do know with biosimilars being interchangeable, which is a real positive, so our focus is really on displacing the originator for us with BYOOVIZ.
因此,這讓我們有一種獨特的互動方式。就 BYOOVIZ 而言,我認為如 Mark 所說,我們確實知道生物相似藥具備可互換性(interchangeable)是一個很大的正面因素,因此我們的重點其實是用 BYOOVIZ 來取代原研藥。
But one of the things we do see is early in the buy-and-bill cycle that Mark alluded to was, accounts and physicians still are going to go through that process of, although a common molecule, is they are going to go through the process of, one, validating reimbursement and all of those different details that give them further encouragement.
但我們確實看到的是,在 Mark 提到的「買入並開立帳單」(buy-and-bill)循環早期,客戶與醫師仍會走過那個流程:即便是相同的分子,他們仍會經歷一個過程——第一,確認給付/報銷(reimbursement)以及所有不同的細節,這些都會讓他們更有信心。
We are on the other side of that at this point in time, and we have very clearly segmented our business in Q4 to focus on growth, and like Mark had said, to reiterate, that we are seeing early signs in Q4 with acceleration building on Q3.
就目前而言,我們已經走過那個階段;而且我們在第四季非常清楚地把業務做了分眾,以聚焦成長;並且如 Mark 所說、再強調一次,我們在第四季看到一些早期跡象,顯示在第三季基礎上加速成長。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
And in terms of the market opportunity for OPUVIZ and the EYLEA 2 mg biosimilar is, in terms of volume, meaningfully higher. The number of accounts that will use OPUVIZ is significantly higher than those that use BYOOVIZ.
至於 OPUVIZ 與 EYLEA 2 mg 生物相似藥的市場機會,就量的角度而言,顯著更高。會使用 OPUVIZ 的客戶數量,將明顯高於使用 BYOOVIZ 的客戶數量。
Steve Seedhouse - Analyst
Steve Seedhouse - Analyst
Yeah. Just to follow up, on the reimbursement and net price sort of side of things for BYOOVIZ, how has that been going relative to your expectations?
好的。再追問一下,關於 BYOOVIZ 的給付/報銷以及淨價格(net price)這一塊,進展相較於你們的預期如何?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Andrew, do you want to comment on that? I do not know that we can give a lot of color on net pricing, but maybe contracting progress.
Andrew,你要評論一下嗎?我不確定我們能在淨定價上提供太多細節,但也許可以談談合約/簽約進度。
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Yeah, Steve, to Mark's point, we are not going to comment on the net pricing of the product, just given the competitive dynamics. But in regards to coverage, I think we have been really pleased with the coverage that we have been able to get on the product. I think it is to your earlier question about learnings going into the OPUVIZ launch, there is a lot of learnings too as part of that, going into that launch on the market access side and on the payer side, that I think is going to be really advantageous for us.
是的,Steve,如 Mark 所說,基於競爭態勢,我們不會評論該產品的淨定價。但就覆蓋(coverage)而言,我認為我們對於能為產品取得的覆蓋範圍感到非常滿意。我想回到你先前關於 OPUVIZ 上市前學習的問題,在市場准入(market access)與付款方(payer)端,我們也累積了很多學習,我認為這對我們會非常有利。
But so far, it has been pretty receptive with the payers. I have been pleased, and I think the commercial team has been pleased with the uptake on the payer side.
但到目前為止,付款方的反應相當正面。我很滿意,我認為商業團隊也對付款方端的採用情況感到滿意。
Steve Seedhouse - Analyst
Steve Seedhouse - Analyst
Thanks so much.
非常感謝。
Operator
Operator
Tom Shrader, US Bank.
Tom Shrader,美國銀行(US Bank)。
Thomas Shrader - Equity Analyst
Thomas Shrader - Equity Analyst
Congratulations on all the progress. Very related questions on BYOOVIZ. Do you have a clear sense of what people testing the water want to see? Is it that you help them with reimbursement? It's that your supply chain is easy? Do you know what they're looking for?
恭喜你們取得所有進展。關於 BYOOVIZ 有幾個非常相關的問題。你們是否清楚那些「先試水溫」的人想看到什麼?是你們協助他們處理給付/報銷嗎?是你們的供應鏈很容易嗎?你們知道他們在找什麼嗎?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Well, we haven't really surveyed the accounts, but by and large, on a buy-and-bill product, as I said, it's the same sort of purchasing cycle that we've seen with IHEEZO, that we've seen with TRIESENCE, and really all of our buy-and-bill products. They buy the product, but they need to make sure that if they purchase it, they're going to get paid for it.
嗯,我們其實沒有正式去調查這些客戶,但總體而言,對於買入並開立帳單(buy-and-bill)產品,如我所說,這是我們在 IHEEZO、TRIESENCE,以及我們所有 buy-and-bill 產品上都看過的同一種採購循環。他們會先購買產品,但他們需要確保:如果他們買了,最後是能拿到款項的。
So it's one thing to be successful on the buy side, but remember, it's buy and bill, and the billing piece has got to come through. That's a key feature that they're investigating when they make these sort of initial purchases. And we're seeing that follow-through, and that's really important, and it's showing up in the numbers in the fourth quarter for BYOOVIZ, and we're going to take all of those learnings into 2027 when we launch OPUVIZ.
所以,在「買入」端成功是一回事,但請記得這是 buy and bill,「開立帳單/請款」那一段必須順利完成。當他們做這類初期採購時,這是他們正在查核的一個關鍵特徵。而我們正在看到後續的持續採購,這非常重要;它也反映在第四季 BYOOVIZ 的數字上;我們也會把所有這些學習帶到 2027 年 OPUVIZ 上市時。
Keep in mind, Tom, we own the largest portfolio of buy-and-bill products in all of ophthalmology. I don't think any company has the number of buy-and-bill products that we have. So we have within our team extraordinary experience on the buy-and-bill side of things.
Tom,請記住,我們擁有全眼科領域最大規模的 buy-and-bill 產品組合。我不認為有任何公司擁有像我們這麼多的 buy-and-bill 產品。因此,我們團隊在 buy-and-bill 這一塊擁有非常豐富的經驗。
Thomas Shrader - Equity Analyst
Thomas Shrader - Equity Analyst
Then on the QUELL trial, for a mixed trial like that, is the rule that if you can get it published, then you can market the data and sort of stress the pieces you wanted? Are there any rules for what you can do for a mixed trial like that? And a quick follow up, just on TRIESENCE, how much of the original market, when the other people had it at peak, have you now filled? Thanks.
那麼關於 QUELL 試驗,對於那種混合型試驗(mixed trial),規則是否是:只要你能發表(published),就可以用於行銷該數據,並且某種程度上強調你想要的部分?對於那種混合型試驗,你們能做什麼有任何規範嗎?另外快速追問一下 TRIESENCE:當其他公司在高峰期擁有該市場時的原始市場規模,你們現在已經填補了其中多少?謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Sure. Well, I'm going to take the second question and give the first to Amir. In terms of TRIESENCE is being used in an area, inflammation for ocular surgery, that we know very well within our company. It is the basis of how we started our company. We started selling compounded triamcinolone acetonide into the cataract surgery market as a compounded medication back in 2014. So we have tremendous history.
好的。我先回答第二個問題,第一個交給 Amir。就 TRIESENCE 而言,它用於一個我們公司非常熟悉的領域——眼科手術的發炎控制。這也是我們公司起家的基礎。我們在 2014 年就開始把複方(compounded)的曲安奈德(triamcinolone acetonide)作為複方藥物,銷售到白內障手術市場。因此我們有非常深厚的歷史。
That compounded product has been used in over 1 million cataract surgeries by thousands of ophthalmologists in the US market. So we know the market in this space extremely well and what the size is, what the addressable market is, the opportunity. Even though we reported 20,000 units in the third quarter, it is really a very small percentage of the overall market opportunity for that product.
那個複方產品已在美國市場被數千名眼科醫師用於超過 100 萬例白內障手術。因此,我們非常了解這個領域的市場:規模多大、可觸及市場(addressable market)是多少、機會在哪裡。即便我們在第三季報告了 20,000 單位,這其實只占該產品整體市場機會中非常小的一部分。
I've been talking about how confident we are in TRIESENCE for now, I guess, a couple of years. Look, the units and the volumes for the quarters following me beginning to talk about how excited I was about relaunching TRIESENCE were not very impressive. What I think you're starting to see is the overall assessment that I had a couple of years ago was on track. It was just a little bit late, and you're starting to see that pick up.
我談到我們對 TRIESENCE 有多有信心,現在大概已經講了——我想——好幾年了。坦白說,在我開始談我對重新上市 TRIESENCE 有多興奮之後的幾個季度,單位數與出貨量並不怎麼亮眼。我認為你現在開始看到的是:我在幾年前做的整體判斷是正確的。只是來得稍微晚了一點,而你現在開始看到它回升。
It is not easy to grow sequentially the way the unit volumes in TRIESENCE are growing now. We have an incredible team. The surgical team has done a wonderful job, Chad and Mike and the rest of the team. We're very bullish on TRIESENCE continuing to grow. We have not really, I think our penetration is certainly in the low single digits.
要像 TRIESENCE 現在這樣在單位出貨量上逐季成長並不容易。我們有一支非常出色的團隊。外科團隊做得非常好,Chad、Mike 以及團隊其他成員。我們非常看好 TRIESENCE 將持續成長。我們目前的滲透率其實還沒有很高,我認為肯定仍在低個位數百分比。
We got a lot of headroom with TRIESENCE. The key factor, before I turn it over, is the clinical outcomes. The clinical outcomes anecdotally on the use of TRIESENCE, all of these new use cases that are causing this increase in volume, the clinical outcomes are extraordinary. They're outstanding, the one-day post-ops that we hear about anecdotally.
我們在 TRIESENCE 上還有很大的成長空間。在我把話交出去之前,關鍵因素是臨床結果。就 TRIESENCE 的使用而言,從一些軼聞經驗來看,所有這些帶動用量增加的新使用情境,其臨床結果都非常卓越。
What we're really excited about is Amir's got this TRIESENCE study going, and we're going to be able to, once again, just like with IHEEZO and the QUELL study, we're going to go from the anecdote to the actual. We're going to have a data set to present that I think is going to fuel further adoption of TRIESENCE. That was a long answer, but I do want to turn it over to Amir on QUELL to comment.
我們真正感到興奮的是 Amir 正在進行這項 TRIESENCE 研究,而我們將能夠再次做到——就像 IHEEZO 與 QUELL 研究一樣——把軼聞變成實證。我們會有一套可呈現的數據,我認為這將推動 TRIESENCE 的進一步採用。這回答有點長,但我確實想把話交給 Amir,請他就 QUELL 發表評論。
Amir Shojaei - Chief Scientific Officer
Amir Shojaei - Chief Scientific Officer
Thanks for the question. I think the way I position this is we are at the infancy of the data review right now. We have top-line results. We anticipate to have the full data. As you alluded, we will have the study published and presented. At that point, the whole sort of premise behind the study would be medical messaging.
謝謝你的提問。我認為我對此的定位是:我們目前正處於數據審閱的初期階段。我們已經有初步的總體結果。我們預期會取得完整數據。如你所提到的,我們會將研究發表並進行展示。到那個時點,這項研究背後的整體前提將會是醫學訊息傳遞。
We have a very strong medical team, and we would be messaging this across the relevant media and conferences. This study as a whole had the rigor to be a peer-reviewed journal published study, and as such, we anticipate to take it to that route with the investigators involved. So that's our plan.
我們有非常強的醫學團隊,會透過相關媒體與會議來傳遞這些訊息。整體而言,這項研究具備足夠嚴謹性,可在同儕審查期刊上發表,因此我們預期會與參與的研究者一起走這條路徑。這就是我們的計畫。
Thomas Shrader - Equity Analyst
Thomas Shrader - Equity Analyst
Okay, great. Thanks for all the details.
好的,很棒。謝謝你提供所有細節。
Operator
Operator
Daniel Clark, Leerink Partners.
Daniel Clark,Leerink Partners。
Daniel Clark - Equity Analyst
Daniel Clark - Equity Analyst
Just first question I wanted to ask on the 2026 revenue guide. Just curious what scenarios you're kind of thinking about to get to the high and low ends of the range here for sales. Thank you.
我第一個問題想問 2026 年的營收指引。想請教你們在銷售區間的高端與低端,分別是基於哪些情境假設來思考的。謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Andrew, do you want to tackle that one?
Andrew,你要回答這題嗎?
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Yeah. I'll do my best, Daniel, without providing. Typically, we don't provide product-level specific guidance, and so we talked a lot about the bridge to get there in the letter to shareholders and in the deck. We expect to see growth quarter over quarter from VEVYE. We're going to get continued contribution from TRIESENCE. Should see sequential growth from IHEEZO as well.
好。我會盡力回答,Daniel,但不會提供——一般而言,我們不提供到單一產品層級的具體指引;我們在致股東信與簡報中已經談了很多達成目標的橋接因素。我們預期 VEVYE 會呈現逐季成長。我們也會持續獲得 TRIESENCE 的貢獻。IHEEZO 也應該會有連續性的成長。
BYOOVIZ, as we've talked a lot about in the Q&A here, we're seeing continued growth there heading into Q4, and Q4 is going to be a really strong quarter for that product based on the early progress we've seen. Then you've got the contribution from TYRVAYA. I know we didn't provide quarterly guidance on TYRVAYA, but you can read in the MD&A, of the Q, we expect that product to do over $30 million of revenue next year.
BYOOVIZ,如同我們在這裡的問答中多次提到的,我們看到它在進入第四季前仍持續成長,而根據我們看到的早期進展,第四季對該產品將會是非常強勁的一季。接著還有 TYRVAYA 的貢獻。我知道我們沒有提供 TYRVAYA 的季度指引,但你可以在該季的 MD&A 中看到,我們預期該產品明年營收將超過 3,000 萬美元。
That product is a pharmacy benefit product, is going to have its best quarter in Q4. So we get the benefit of that product's best quarter being here at the end of 2026 and contributing to revenue where we haven't gotten that benefit earlier in the year. Then we're always working on things, and so we've got some other aspects of the business on the commercial side that we're working on that could help us push beyond the low end of the guided range.
該產品屬於藥局福利(pharmacy benefit)產品,第四季會是它表現最好的一季。因此,我們能在 2026 年底享受到該產品最佳季度所帶來的挹注,而在年初則尚未享有這個效益。此外,我們也一直在推進各項工作,因此在商業端還有一些我們正在進行的其他業務面向,可能有助於我們把表現推升到指引區間低端之上。
Daniel Clark - Equity Analyst
Daniel Clark - Equity Analyst
Okay, got it. Super helpful. Just to follow up, on HarrowRx, just curious, are there any products or particular use cases where you think this meaningfully improves provider experience, and just how you're thinking about the opportunity from this launch would be great. Thank you.
好的,了解。非常有幫助。再追問一下關於 HarrowRx:想請教是否有任何產品或特定使用情境,你們認為它能顯著改善醫療提供者的體驗?以及你們如何看待這次上線所帶來的機會?謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Sure. Thank you for that, Daniel. Yeah, HarrowRx is actually a really important platform for our company in that when I go out on the road and I talk to our sales reps who are in offices every day, meet with staff in particular at these offices who have to deal with the challenges of prescribing pharmacy benefit products, they're using one specialty pharmacy for a product by a competitor. They're using a different specialty pharmacy for VEVYE, for example.
當然。謝謝你,Daniel。是的,HarrowRx 對我們公司其實是一個非常重要的平台。因為當我外出拜訪、與我們每天在診所跑線的業務代表交流時,特別是與這些診所裡必須處理開立藥局福利產品處方之挑戰的行政人員交流時,他們可能為了競品的一個產品使用某一家專科藥局。例如,他們又為 VEVYE 使用另一家不同的專科藥局。
Fortunately, TYRVAYA was available from PhilRx, which is our specialty pharmacy partner. But what we have to offer our offices, and this is something I hear day in and day out when I talk to our customers, they're always surprised at the breadth of our portfolio. They're surprised that we have NATACYN, that we have VERKAZIA, ILEVRO, FLAREX. I can go down the list.
所幸 TYRVAYA 可透過 PhilRx 取得,而 PhilRx 是我們的專科藥局合作夥伴。但我們能提供給診所的是——這也是我每天與客戶交談時一再聽到的——他們總是對我們產品組合的廣度感到驚訝。他們驚訝我們有 NATACYN、有 VERKAZIA、ILEVRO、FLAREX。我可以把清單一路列下去。
What they are interested in is a single point of access for the entirety of our portfolio. In the future, we believe at Harrow that more prescribing is going to take place through these sorts of specialty hubs. If you were to get a prescription for ILEVRO and send it to your local CVS, odds are they do not have that product in stock for you to pick up in an hour or two, so they have to order it in.
他們感興趣的是:能以單一入口存取我們整個產品組合。我們相信未來在 Harrow,更多的處方開立將會透過這類專科樞紐(specialty hubs)來進行。如果你拿到 ILEVRO 的處方並送到你家附近的 CVS,很可能他們並沒有現貨讓你在一兩個小時內取藥,因此他們必須另外訂貨。
We believe going forward, if we can provide that single access point for this very large product portfolio, now I think we have over 20 branded products, we think that is a very attractive platform for doctors and their staff to be able to utilize, to be able to access prior authorizations and all sorts of other features that we have planned for the platform.
我們相信未來,如果我們能為這個非常龐大的產品組合提供單一存取點——我想我們現在有超過 20 個品牌產品——我們認為這對醫師及其團隊而言是一個非常有吸引力的平台,可供他們使用;也能用來處理事前授權(prior authorizations)以及我們為該平台規劃的各種其他功能。
It will be an important part of our business. It will be a single point of access for the entirety of our portfolio, and I do not believe any of our other competitors really have anything like that.
它將成為我們業務的重要一環。它會是存取我們整個產品組合的單一入口,而我不認為其他競爭對手真的有類似的東西。
Operator
Operator
Mayank Mamtani, B. Riley Securities.
Mayank Mamtani,B. Riley Securities。
Mayank Mamtani - Analyst
Mayank Mamtani - Analyst
Appreciate the level of detail here. If I may ask on the VEVYE new patient start trends, Mark, that seems strong. Are you able to comment on where these are sort of coming from? Are these switches from generic cyclosporine or other branded options, or these are new to prescription patients? I wonder if the mix in any way is shifting now that you have a fully deployed sales force and payer coverage is also expanding.
感謝你們提供如此細緻的說明。如果可以的話,我想問 VEVYE 的新病患起始用藥趨勢,Mark,看起來相當強勁。你能否評論一下這些新起始大致是從哪裡來的?是從學名環孢素(generic cyclosporine)或其他品牌選項轉換而來,還是這些病患是首次開始使用處方藥?我也想知道,在你們的銷售團隊已全面部署、且付款方覆蓋也在擴大之際,這個組合是否在某種程度上正在改變。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Yeah. The truth is, we don't know what is causing the stability and growth in our new prescription volumes. When we put these rules in place, we anticipated volumes may be coming down, that we might have to sacrifice volume in order to improve net pricing. That has simply, fortunately, not been the case. We've actually been able to grow new prescription starts despite these new rules, this new algorithm that actually improves net pricing and is improving net pricing for us.
是的。事實是,我們不知道是什麼造成我們新處方量的穩定與成長。當我們導入這些規則時,我們原本預期量可能會下滑,可能必須為了改善淨定價而犧牲一些量。但幸運的是,情況並非如此。儘管有這些新規則、這套實際上能改善淨定價、並且正在為我們改善淨定價的新演算法,我們仍然能夠提升新處方起始量。
I think that's a really positive development for the VEVYE franchise. In terms of where they're coming from, though, as I said, we don't know. When I put VEVYE in my eye, and I do, and I put the other choices in my eye, I don't know why anyone would start anything other than VEVYE. It feels great, it works fast, it has a durable treatment effect.
我認為這對 VEVYE 產品線來說是非常正面的發展。至於它們是從哪裡來的,如我所說,我們不知道。當我把 VEVYE 點進眼睛裡——我確實有用——再把其他選項點進眼睛裡,我不明白為什麼有人會選擇從 VEVYE 以外的任何產品開始。它感覺很好、起效快,而且治療效果持久。
The data's incredible, and it just feels phenomenal. Like I said, I don't know why anyone would use anything other than VEVYE, but some people do. As I think you're alluding to in your question, more and more people are starting with VEVYE, and I expect that trend to continue.
這些數據令人難以置信,感覺非常出色。就像我說的,我不知道為什麼有人會用 VEVYE 以外的任何產品,但確實有人這麼做。正如我想你在問題中所暗示的,越來越多人一開始就選用 VEVYE,我預期這個趨勢會持續下去。
Mayank Mamtani - Analyst
Mayank Mamtani - Analyst
Great. Just a couple more quickly. On the IHEEZO step-up in 4Q, to the extent possible, if you're able to quantify year over year, and also from a restocking and net price per unit reset we got in 2Q. Just broadly, should we think about this in alternate quarter buying cycles, like 2Q and 4Q being strong? Or is it, as we think about next year, and I know you're not guiding for next year today, it's basically a 2Q to 4Q steady build with a 1Q sort of reset?
很好。再快速問兩個。關於 IHEEZO 在第四季的拉升,在可能的範圍內,如果你能量化一下年對年變化,以及我們在第二季看到的補庫存與每單位淨售價重置所帶來的影響。概括來說,我們是否應該把它理解為交替季度的採購週期,例如第二季和第四季較強?或者,當我們思考明年(我知道你今天不會對明年提供指引)時,基本上是從第二季到第四季穩步走高,而第一季有點像重置?
Then maybe just for Amir, on the G-MELT NDA filing, which elements have been fast-tracked, if you could comment, and any thoughts from the pre-NDA meeting you may have had on how to think about the combination product scheduling, as obviously you prepare for commercial readiness? Thanks for taking the question.
另外也許給 Amir 一個問題:關於 G-MELT 的 NDA 申報,哪些要素已被加速審查(fast-tracked),如果你能評論一下;以及你們可能在 pre-NDA 會議中得到的想法,對於如何看待複方產品(combination product)的排程(scheduling),因為你們顯然也在為商業化就緒做準備?謝謝讓我提問。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Yeah. Mayank, thanks for the question. I'll do a comment on IHEEZO and by not commenting or trying to answer your question. We really do not want to be in the business, and I think I said this in the letter to stockholders, of giving quarterly guidance on a product-specific basis. IHEEZO in particular can be choppy quarter to quarter. That said, the fourth quarter is always, as we said in the letter and I think talked about on this call, the strongest period for that product.
好的。Mayank,謝謝你的問題。我會就 IHEEZO 做個評論,但其實是不評論、也不試著直接回答你的問題。我們真的不希望從事——我想我也在致股東信中提過——以單一產品為基礎提供季度指引這件事。IHEEZO 尤其可能在季度之間波動很大。不過,第四季一向是——正如我們在信中所說、也在這通電話會議中談到——該產品最強的期間。
Look, second quarter's good, the first quarter wasn't bad. This year in particular, there were some challenges with realizing revenue with IHEEZO, and I think we've talked about that many times on prior calls. I think in 2027, you're going to see a normalization of what to expect with IHEEZO.
你看,第二季表現不錯,第一季也不差。尤其是今年,IHEEZO 在收入認列上遇到一些挑戰,我想我們在之前多次電話會議中已談過很多次。我認為到 2027 年,你會看到 IHEEZO 的表現回到較正常、可預期的水準。
I can only tell you one thing with IHEEZO, 2027 is going to be a stronger year for volumes and revenue for IHEEZO than 2026, just like 2026, I think, ultimately, in terms of demand, certainly, was stronger than the prior year. Amir, do you want to comment on the G-MELT filing at all? I do not know that you can say much about our pre-NDA meeting. Certainly, if we are going to actually submit to the FDA, it must have gone fairly well.
我對 IHEEZO 只能告訴你一件事:2027 年 IHEEZO 的銷量與營收會比 2026 年更強;就像我認為 2026 年最終在需求面上,確實也比前一年更強。Amir,你要不要就 G-MELT 的申報補充一下?我不確定你能對我們的 pre-NDA 會議說多少。當然,如果我們真的要向 FDA 提交申請,那表示會議進展應該相當順利。
Amir Shojaei - Chief Scientific Officer
Amir Shojaei - Chief Scientific Officer
Yeah, I think I concur with that. The meeting was productive, and we are aligned with, or more importantly, we are submitting what the FDA anticipates to receive. So from that regard, we are on the right foot, and we will be submitting, hopefully by end of this month, if not beginning of next month. That said, our anticipation is we will have a PDUFA goal date next year. Whether it is priority review or not, that will be part of the decision the FDA would make.
是的,我同意這點。那次會議很有成效,我們也與 FDA 的期待保持一致——更重要的是,我們提交的內容正是 FDA 預期會收到的。因此在這方面我們起步正確,我們希望能在本月底前提交,若不行也會在下月初。此外,我們預期明年會有一個 PDUFA 目標日期。是否屬於優先審查(priority review),將由 FDA 作出決定。
Beyond that, I think from a scheduling perspective, that would be a review during the submission as well. We are moving forward with our anticipated scheduling between the two fixed-dose combination products.
除此之外,我認為從排程(scheduling)的角度來看,這也會在提交後的審查過程中一併評估。我們正依照對兩個固定劑量複方產品(fixed-dose combination products)的預期排程持續推進。
Mayank Mamtani - Analyst
Mayank Mamtani - Analyst
Great. Thanks so much, guys.
太好了。非常感謝,各位。
Operator
Operator
Thomas Flaten, Lake Street Capital.
接下來是 Lake Street Capital 的 Thomas Flaten。
Thomas Flaten - Analyst
Thomas Flaten - Analyst
Following up on a couple questions. First for Amir, and I apologize if I missed this, but do you have a hypothesis on why you came up 30 points or so short of the 88% anesthesia goal that you had set for the study?
我追問幾個問題。第一個給 Amir,不好意思如果我漏聽了:你是否有一個假設,為什麼你們的結果比研究設定的 88% 麻醉目標少了大約 30 個百分點?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Great question. Amir, you want to tackle that one?
問得很好。Amir,你要回答這題嗎?
Amir Shojaei - Chief Scientific Officer
Amir Shojaei - Chief Scientific Officer
Yeah, thank you for that question. Frankly, this was the first set of adequate and well-controlled study that would generate that answer to your question. We believe the hypothesis lies is really the relevant difference between a procedure that requires cutting the eye as opposed to a procedure that requires deep penetration into the eye. That's where the delta is how, and I think Mark alluded to this, how do you anesthetize the eye?
好的,謝謝你的問題。坦白說,這是第一組足夠且良好對照(adequate and well-controlled)的研究,能產生你這個問題的答案。我們認為假設的關鍵,確實在於兩種手術之間的相關差異:一種是需要切開眼球的處置,另一種則需要深入穿透眼球的處置。差異就在於——我想 Mark 也提到過——你要如何對眼睛進行麻醉?
When you compare the various procedures, you realize there are different numbers that you would have to set your bar for. We set the bar, we extrapolated with the existing data because there was no other data available. With this data in hand, we have obviously learned the actual benchmark that we should have set the study at. But that's really the gist of it. It's borrowed from or extrapolated from a different procedure because there were no other data available.
當你比較不同的處置時,你會發現你必須設定的門檻數值並不相同。我們當時設定的門檻,是基於既有數據做推估,因為沒有其他可用數據。現在有了這些數據,我們顯然已經學到,研究應該設定的實際基準(benchmark)是什麼。但重點大致就是如此。因為沒有其他數據可用,所以是借用或從另一種處置推導(extrapolated)而來。
Thomas Flaten - Analyst
Thomas Flaten - Analyst
Got it. I appreciate the --
了解。我很感謝——
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
I just want to add to that, by the way, because it's very interesting. When we launched IHEEZO, I can't tell you how many doctors said to us anesthesia is not a problem. We don't have a problem that you're going to be able to help us solve. I think if you look at the data from QUELL, what it clearly says is, patients experience pain from these injections. It seems axiomatic that if you're going to put a needle into the sclera of someone's eye, that it might be painful.
順帶一提,我想再補充一下,因為這非常有意思。我們推出 IHEEZO 時,我無法告訴你有多少醫師跟我們說麻醉不是問題。我們沒有你能幫我們解決的問題。我認為如果你看 QUELL 的數據,它清楚顯示病人在這些注射中會感到疼痛。如果你要把針插入某人的眼球鞏膜(sclera),那可能會痛,這似乎是不言自明的。
I think the study certainly demonstrates that. It also shows that whether you're going to anesthetize the eye with an injection of lidocaine, sort of a needle before a needle, or you want to use something topical like IHEEZO, you can pretty much get patients to about the same level.
我認為這項研究確實證明了這點。它也顯示,不論你是用利多卡因(lidocaine)注射來麻醉眼睛——有點像「針前再打一針」——或是你想用像 IHEEZO 這樣的局部外用(topical)方式,你基本上都能讓病人的疼痛程度達到差不多的水平。
In fact, Amir alluded to the fact that the pain levels between the two cohorts were essentially the same, at two. What we're excited about and what we're now able to message lawfully through our medical team is the patient experience after the injection.
事實上,Amir 提到兩個隊列(cohorts)之間的疼痛程度基本相同,大約是 2。我們感到興奮、而且現在也能透過我們的醫療團隊在合規(lawfully)的前提下對外傳達的是:注射後的病人感受(patient experience)。
It's so important that these offices not get the calls from their patients who are experiencing pain because they may have gotten an injection of lidocaine post-procedure, or that they have some ocular surface trauma, or that they've experienced some other adverse event associated with the intravitreal injection.
這非常重要,因為這些診所不應該接到病人打來的電話,說他們因為術後打了利多卡因而感到疼痛,或是有一些眼表(ocular surface)創傷,或是經歷了與玻璃體內注射(intravitreal injection)相關的其他不良事件。
To be able to now message that is so important for us. I think going forward, it's a data set that will inure to the benefit of IHEEZO, that will be helpful to our reps. It will justify certainly the use of IHEEZO in practice for more practices. We're really quite pleased with the data set that we invested in. Could have been better, by the way.
現在能夠傳達這一點,對我們來說非常重要。我認為往後看,這套數據將會讓 IHEEZO 受益,對我們的業務代表也會很有幫助。它當然會支持更多診所在臨床實務中使用 IHEEZO。我們對這套投入所得到的數據集非常滿意。順帶一提,本來可以更好。
Thomas Flaten - Analyst
Thomas Flaten - Analyst
I appreciate that. Thank you.
我理解。謝謝。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Could have been better, but it was pretty doggone good.
本來可以更好,但已經相當、相當不錯了。
Thomas Flaten - Analyst
Thomas Flaten - Analyst
No, that's great. Thanks, Mark. Then follow up for Pat. You mentioned the new territory design and the ocular surface team, but could you just maybe flesh that out a little bit more? So you've got effectively three teams coming together. You've got seven products.
不,這很棒。謝謝你,Mark。接著追問 Pat:你提到新的區域(territory)設計以及眼表團隊(ocular surface team),但你能不能再多補充一點?所以你基本上是把三個團隊整合在一起。你們有七個產品。
Are you overlapping in territories? Did you split territories to create more frequency in smaller groups? Can you talk a little bit more about what that territory design looks like and how your incentive compensation looks with a seven-product bag?
你們在區域上是否有重疊?你們是否拆分區域,以便在較小的團隊中提高拜訪頻率?你能否再多談一點這種區域設計的樣貌,以及在七項產品組合下你們的激勵性薪酬制度是如何設計的?
Patrick Sullivan - Chief Commercial Officer
Patrick Sullivan - Chief Commercial Officer
Yeah. Thanks for the question. On our prior earnings call, and I think through the prior communications, obviously, this has been a very phased and disciplined plan that started earlier this year. If you recall, the organization made a large commitment, and I think to further expand our presence in the dry eye space to really get behind VEVYE, and if you recall, earlier this year.
是的。謝謝你的提問。在我們上一通財報電話會議上,以及我想在先前的溝通中也有提到,很明顯,這是一個非常分階段且有紀律的計畫,於今年稍早開始。如果你還記得,組織做出了很大的承諾,我想是為了進一步擴大我們在乾眼領域的布局,真正全力支持 VEVYE;而且如果你還記得,今年稍早。
So right now, what we've done is, to your point, we've taken three teams, the very talented Viatris team with the acquisition of TYRVAYA. We had a specialty team, as Mark mentioned, that was representing a few of our specialty products, such as, like Mark mentioned, these more rarer products, VERKAZIA and IOPIDINE, and also brought that together in our dry team. So that is our ocular surface team.
所以目前我們所做的,如你所說,我們把三個團隊整合在一起:透過收購 TYRVAYA 而加入的、非常優秀的 Viatris 團隊;我們也有一支專科團隊,如 Mark 提到的,原本負責我們幾項專科產品,例如 Mark 所提到的較罕見產品 VERKAZIA 和 IOPIDINE;並且也把這些整合到我們的乾眼團隊中。因此,這就是我們的眼表團隊。
What I would say is one of the things that we're really excited about is we were very methodical in, one, looking at a really clear approach that, one, we cover the right physicians to make sure that we have the right prioritization on products to deliver the right promotional intensity to drive the outcome that we're looking for.
我想說,我們非常興奮的一點是,我們在方法上非常嚴謹:第一,採用非常清晰的做法來檢視,確保我們覆蓋到正確的醫師;同時確保產品的優先順序設定正確,以提供適當的推廣強度,來推動我們所追求的成果。
Our main focus is heavily on VEVYE. VEVYE, as you see our prescription trends, we've had a pretty significant growth over the prior quarter of 17%, I think 83% year over year. I think we're really excited that we're just getting started, and we hear consistent feedback early in our new model about how we're deploying in a very smart, sophisticated way that drives increased productivity. In a word for us, our prioritization is VEVYE, and also our dry eye portfolio.
我們的主要重點高度聚焦在 VEVYE。從你看到的處方趨勢來看,上一季相較前一季我們有相當顯著的成長,約 17%,我想年增約 83%。我們非常興奮,因為我們才剛開始;而且在新模式的早期,我們持續收到一致的回饋,認為我們以非常聰明、成熟的方式進行部署,帶動生產力提升。用一句話來說,我們的優先順序是 VEVYE,以及我們的乾眼產品組合。
I think by leveraging the other products that we have allow us to show up in a really unique way that only Harrow can with the breadth of our products, that really, if you think about it now, we have a really premium cornerstone spot when it comes to VEVYE as the leading dry eye disease product. With TYRVAYA, FRESHKOTE, and FLAREX, it really makes a real unique combination in our portfolio.
我認為,善用我們其他產品,讓我們能以一種非常獨特的方式出現在市場上,這是只有 Harrow 能做到的,因為我們擁有廣泛的產品線;如果你現在這樣想,我們在 VEVYE 方面已經占據非常高端、關鍵的定位,作為領先的乾眼疾病產品。再加上 TYRVAYA、FRESHKOTE 與 FLAREX,讓我們的產品組合形成非常獨特的搭配。
Make no mistake, VEVYE is our lead product that is getting the most emphasis and the most promotional intensity. To answer your question is, we have a very clear plan. This is just now taking shape. This is really going to help propel us to the next level of growing not only our whole portfolio, but specifically VEVYE, moving forward. More prescribers, more productivity, and more prescriptions.
毫無疑問,VEVYE 是我們的主打產品,獲得最多的重點與最高的推廣強度。回答你的問題:我們有一個非常清晰的計畫。這個計畫現在才剛開始成形。這將真正幫助我們邁向下一個層級,推動不僅是整體產品組合的成長,尤其是未來 VEVYE 的成長。更多開立醫師、更高生產力、以及更多處方。
Thomas Flaten - Analyst
Thomas Flaten - Analyst
That's great. Thanks, everyone.
太好了。謝謝各位。
Operator
Operator
Jeffrey Cohen, Ladenburg Thalmann & Company.
Jeffrey Cohen,Ladenburg Thalmann & Company。
Jeffrey Cohen - Analyst
Jeffrey Cohen - Analyst
Two for Amir, I guess. Firstly, maybe for Mark or Amir, can you talk about the TRIESENCE Phase 3 and enrollment, how it's going, when we may expect that to complete, and what we may see as far as press releases or filing dates?
我想有兩個問題給 Amir。第一個,也許給 Mark 或 Amir:你能談談 TRIESENCE 第三期試驗與收案進度嗎?目前進展如何?我們大概何時可預期完成收案?以及在新聞稿或申報時程方面,我們可能會看到什麼時間點?
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Sure. Amir, do you want to talk about that study?
當然。Amir,你想談談那項研究嗎?
Amir Shojaei - Chief Scientific Officer
Amir Shojaei - Chief Scientific Officer
Yeah, thanks for the question. Our program for TRIESENCE is going forward well. We are enrolling on track. We still anticipate readout next year, specifically towards the end of first quarter, beginning of second quarter. That's our sort of current progression.
好的,謝謝你的提問。我們的 TRIESENCE 計畫進展良好。我們的收案按計畫進行。我們仍預期明年會有讀出結果,具體而言是在第一季末、第二季初左右。這是我們目前的進度規劃。
Jeffrey Cohen - Analyst
Jeffrey Cohen - Analyst
Perfect. Okay, thanks for that. Secondly, I guess a question for Andrew. Could you talk about R&D for the quarter and maybe give us a sense of what you'd expect on R&D, perhaps for Q4, or just generally speaking as far as levels go? I know you've been quite active on a number of fronts on the development side.
很好。好的,謝謝。第二個問題我想問 Andrew。你能談談本季的研發費用,並讓我們了解一下你對研發費用的預期嗎?例如第四季,或更一般而言在費用水準上會如何?我知道你們在開發端的多個面向都相當積極。
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Yeah. Thanks, Jeff. On the R&D side, R&D is kind of a, I would say, almost a seasonal spend. It depends on what we have that is active and what we can accelerate. But typically, the expense, I think, as a percent of revenue should be roughly the same as where it is now. That is where we are going to try to pin it to. But if there are opportunities to accelerate or investments that we think can make a significant return, we will go after it.
好的。謝謝你,Jeff。就研發面而言,我會說研發支出有點像是季節性支出。這取決於我們有哪些專案正在進行,以及哪些可以加速。但通常,我認為研發費用占營收的比例應該大致會與目前差不多。這是我們希望把它控制在的水準。不過,如果有可以加速的機會,或是我們認為能帶來顯著回報的投資,我們也會去做。
As we are kind of looking at Q4, we are accelerating some of these programs. We have accelerated programs. Not all of that ends up in R&D, by the way. Some of it goes up into the SG&A line. For example, with the G-MELT NDA filing, not all of that cost that is going to go into that filing and the PDUFA fee that will go with it is going to end up in R&D. There will be parts of it for sure, but other parts will also flow up into SG&A.
當我們在看第四季時,我們正在加速其中一些計畫。我們已經加速了相關專案。順帶一提,並不是所有這些都會計入研發費用。其中一部分會進到 SG&A(銷售、一般及行政費用)項下。例如,針對 G-MELT 的 NDA 申報,並非所有將投入該申報的成本,以及隨之而來的 PDUFA 費用,都會計入研發費用;當然其中一部分會,但其他部分也會流入 SG&A。
Jeffrey Cohen - Analyst
Jeffrey Cohen - Analyst
Perfect. Thanks for taking the questions.
很好。謝謝回答我的問題。
Operator
Operator
Thank you.
謝謝。
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Andrew Boll - President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
Thank you, Jeff.
謝謝你,Jeff。
Operator
Operator
I show no further questions at this time. I will now turn the call back over to Mark for closing remarks.
目前沒有其他提問。我現在把電話交回給 Mark 作結語。
Mark Baum - Chairman of the Board, Chief Executive Officer
Mark Baum - Chairman of the Board, Chief Executive Officer
Thank you, operator, and thanks to everyone for joining us. We are seeing real momentum heading into what we expect to be Harrow's strongest quarter. We look forward to reporting our full-year results and hopefully seeing many of you at our Investor Day in New York City in March. Have a great day.
謝謝主持人,也謝謝各位參與。我們看到在進入我們預期將是 Harrow 最強勁的一季之前,動能正在形成。我們期待公布全年業績,也希望在三月於紐約市舉行的投資人日能見到各位中的許多人。祝各位有美好的一天。
Operator
Operator
This concludes today's conference call. Thank you for participating, and you may now disconnect.
今天的電話會議到此結束。感謝各位參與,現在可以掛線。